[Efficacy of ofloxacin (zanocin) in the treatment of multidrug resistant pulmonary tuberculosis].
Data concerning chemotherapy of patients with multiresistant tuberculosis of the lungs by reserve antituberculous agents in combination with ofloxacin are presented. It was shown that the ofloxacin-including chemotherapy regimen applied to patients with multiresistant destructive tuberculosis of the lungs provided by the end of the 6-month treatment course elimination of multidrug resistant tubercle bacilli isolation at least in 80% of the patients and closure of the lung caverns after artificial pneumothorax and routine surgical interventions in more than half of the patients. For all this, side effects that could not be eliminated were stated merely in 8.5% of the patients.
Mishin
V Iu
VIu
Central Research Institute of Tuberculosis, Russian Academy of Medical Sciences, Moscow.
Vasil'eva
I A
IA
D000284:Administration, Oral; D000328:Adult; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D000995:Antitubercular Agents / Q000627:therapeutic use*; D003967:Diarrhea / Q000139:chemically induced; D024901:Drug Resistance, Multiple, Bacterial / Q000235:genetics; D004359:Drug Therapy, Combination; D005076:Exanthema / Q000139:chemically induced; D006801:Humans; D008875:Middle Aged; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification; D015242:Ofloxacin / Q000009:adverse effects / Q000627:therapeutic use*; D011031:Pneumothorax, Artificial; D016896:Treatment Outcome; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000601:surgery
D000890:Anti-Infective Agents; D000995:Antitubercular Agents; D015242:Ofloxacin